





**Supplemental Figure S1.** Amino-acid site-wise average root mean square fluctuation profiles for the viral bound and unbound ACE2 targets in this study.



**Supplemental Figure S2.** Amino-acid site-wise significance tests for the root mean square fluctuation differences between the viral bound and unbound ACE2 targets in this study. The test of significance is a two sample Kolmogorov-Smirnov test with a Benjamini Hochberg p-value correction to account for the number of sites. The plots show the D value (i.e. test statistic) color coded by p-value with orange indicating p < 0.005, green indicating p < 0.025, aqua indicating p < 0.05 and violet indicating p > 0.05. Here the p-value of the two sample KS test indicates the probability of the viral bound and unbound ACE2 protein dynamics are drawn from the same population.



**Supplemental Figure S3.** Amino-acid site-wise fluctuation profiles and significance tests for the root mean square fluctuation differences between the viral bound and unbound CD26 targets in this study. The test of significance is a two sample Kolmogorov-Smirnov test with a Benjamini Hochberg p-value correction to account for the number of sites. The plots show the D value (i.e. test statistic) color coded by p-value with orange indicating p < 0.005, green indicating p < 0.025, aqua indicating p < 0.05 and violet indicating p > 0.05. Here the p-value of the two sample KS test indicates the probability of the viral bound and unbound ACE2 protein dynamics are drawn from the same population.

HKU1 OC43 SARS-2 SARS-1	1 10 SGFTVKPVATVHRRIPD	20 30 LPDCDIDKWLNNFNVP <b>S</b> LPNCNIEAWLNDKSVP <b>S</b> RVQPTE <b>S</b>	40. 50. PLNWERKIFSNCNFNL PLNWERKTFSNCNFNM IVRFPNITNLC	60 VHTDSFSCNN IQADSFTCNN GEVFNATRFA GEVFNATKFP
HKU1 OC43 SARS-2 SARS-1	70 FDESKIYGSCFKS <b>IV</b> .LI IDAAKIYGMC.FSS <b>I</b> II SVYAWNRKRISNC <b>VA</b> DY SVYAWERKKISNC <b>VA</b> DY	80 90 DKFAIPNSRRSDLQLGS DKFAIPNGRKVDLQLGN SVLYNSASFSTFKCYGV SVLYNSTFFSTFKCYGV	100 SNYKIDTTSSSCQLYY FNYRIDTTATSCQLYY DLCFTNVYADSFVIRGI DLCFSNVYADSFVVKGI	110 SLPAINV NLPAANVS DEVRQIAPGQ DDVRQIAPGQ
HKU1 OC43 SARS-2 SARS-1	120 130 TINNYNPSSWNRRYGFNI VSRFNPSTWNKRFGFIEI TGKIADYNYKLPDDFTG TGVIADYNYKLPDDFMG	140, 150 NSVVYSRYCFSVNNTFC DPAGVLTNHDVVYAQHC CNNLDSKVGGNYNYLYR CRNLDATSTGNYNYKYR	160 PCAKPSFASSCKSHKPI FKAPKNFCPCK LFRKSNL YLRHGKL	170 PSASCP <b>IGT</b> N LNGSCVG <b>S</b> GP KPFERD <b>IST</b> E RPFERD <b>ISN</b> V
HKU1 OC43 SARS-2 SARS-1	180 190 YRVLDHTDWCRCSCLI GKCPAGTNYLTCDNLCT IYCNGVEGFNCYFPLQS PFPCTPPALNCYWPLND	200 2 PDPI <b>T</b> AYDPRSCSQ <b>K</b> KS PDPI <b>TFTG</b> TYKC <b>P</b> QTKS YGFQP <b>ING</b> VGYQ <b>P</b> Y <b>R</b> VV YGFY <b>TTG</b> IGYQ <b>P</b> Y <b>R</b> VV	10 220 LVGVGEHCAGFGGVLD LVGIGEHCSGLAGGNS VLSFELLHGPKK VLSFELLNGPKL	230 GSYNVSCLCS CTCR STNL STDL
HKU1 OC43 SARS-2 SARS-1	<b>240 250</b> TDAFLGWSYDTCVSNNR PQAFLGWSADSCLQGDK VKNKCVNF IKNQCVN	260 2 CNIFSNFILNGINNDLL CNIFANFILHDVN	70 280 QPNTEVFTDVCVDYDL	<b>290</b> YGITGQGIFK

				3	0	ò								3	1	ò								3	2	ò									
HKU1	Е	V	s	A	V	Y	Y	N	s	W	Q	N	L	L	Ι	I	G	F	K	D	F	V	Т	N	K	Т	Y	N	Ι	F	Ρ	С	Y	A	G
SARS-2	1	:	:	:	:	:	:	1	:	:	:	:	:	2	:	:	:	:	:	:	:	:	1	:	:	:	:	1	:	:	:	:	:	:	:
SARS-1		•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•

**Supplementary Figure S4.** MSA of human coronavirus RBD amino acid sequences derived from PDB structures. Boxed in red is the loop region proximal to the second ACE2 touch point, where differences in chemical properties between OC43 and other coronavirus strains can be seen particularly at position 200.



**Supplemental Figure S5.** Structural alignment of the five outbreak models used in our study (tan=SARS-CoV-2(COVID19), aqua=SARS-CoV-1(classic SARS), red=MERS-CoV, lavender=HCov-OC43 and green=HCoV-HKU1).

Close-up image highlights the structural difference at Q325 caused by COVID 19 from the four other models.

**Supplemental Figure S6.** Positional plots of changes to atom fluctuations due to binding in potential zoonotic encounters with novel betacoronavirus spike glycoproteins. The models of zoonotic encounters include (A) bat HKU4 interacting with human CD26 (PDB: 4qzv), (B) bat HKU4 interacting with human ACE2 (from PDB: 6m17), and (C) MERS - CoV virus from PDB: 5x5c interacting with human ACE2 from PDB: 6m17. Note: layout here corresponds to B, C, and D, in Figure 4. Shift in atom fluctuations (Y axis) due to binding were calculated as the signed symmetric Kullback-Leibler divergence of distributions the root mean square time deviations for the residue averaged protein backbone atoms (i.e. N, C $\alpha$ , C and O) on each amino acid (X axis) for ACE2 comparing spike glycoprotein bound versus unbound dynamic state.



**Supplemental Figure S7.** Per-residue rmsf of SARS-CoV-2 RBD in complex with human ACE2 mutated at the K353 position in silico. Mutagenesis was performed with the swapaa command in Chimera v. 1.13 and the structure was minimized with 2000 steps of steepest descent. Residues of interest in comparison to the wild-type SARS-CoV-2 RBD/ACE2 complex are labeled. This mutagenesis study was conducted to validate the ability of the DROIDS 3.0 molecular dynamics tool to corroborate RBD/ACE2 interaction-discouraging amino acid substitution K353A in SARS-CoV-1 [34].



**Supplementary Figure S8.** Per-residue rmsf of SARS-CoV-2 RBD in complex with human ACE2 mutated at various residues in the 386AAQPFLL392 motif in silico. Mutagenesis was performed with the swapaa command in Chimera v. 1.13 and the structure was minimized with 2000 steps of steepest descent. Residues of interest in comparison to the wild-type SARS-CoV-2 RBD/hACE2 complex are labeled.

ILE LEU

LYS

MET PHE

PRO

SER THR

TRP

TYR VAL

LEU

LYS

MET

PHE PRC

SER

THE

TRP

TYR

VAL





position (residue number)

Supplementary Figure S9. Per-residue rmsf of SARS-CoV-2 RBD in complex with human ACE2 mutated at the V739 position to hydrophobic residue leucine and hydrophilic residue glutamate. Mutagenesis was performed with the swapaa command in Chimera v.1.13 and the structure was minimized with 2000 steps of steepest descent. Residues of interest in comparison to the wild-type SARS-CoV-2 RBD/hACE2 complex are labeled.

ILE

LEU

LYS

MET

PHE

PRO SER

TYR

THR TRP TYR VAL





LEU

LYS

PHE

PRC

SEF

THR

TRP





**Supplementary Figure S11.** Per-residue rmsf of SARS-CoV-2 RBD in complex with human ACE2 mutated at the K408 position to alanine. Mutagenesis was performed with the swapaa command in Chimera v. 1.13 and the structure was minimized with 2000 steps of steepest descent. Residues of interest in comparison to the wild-type SARS-CoV-2 RBD/hACE2 complex are labeled.